DENTSPLY SIRONA Inc. $XRAY Shares Sold by Campbell & CO Investment Adviser LLC

Campbell & CO Investment Adviser LLC lessened its position in shares of DENTSPLY SIRONA Inc. (NASDAQ:XRAY) by 67.6% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 58,655 shares of the medical instruments supplier’s stock after selling 122,486 shares during the period. Campbell & CO Investment Adviser LLC’s holdings in DENTSPLY SIRONA were worth $744,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. Trust Co. of Toledo NA OH acquired a new position in shares of DENTSPLY SIRONA in the 2nd quarter valued at about $27,000. Parkside Financial Bank & Trust raised its holdings in DENTSPLY SIRONA by 620.6% in the second quarter. Parkside Financial Bank & Trust now owns 1,715 shares of the medical instruments supplier’s stock valued at $27,000 after buying an additional 1,477 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in DENTSPLY SIRONA during the first quarter valued at approximately $26,000. True Wealth Design LLC grew its stake in DENTSPLY SIRONA by 273.0% during the second quarter. True Wealth Design LLC now owns 2,376 shares of the medical instruments supplier’s stock worth $38,000 after buying an additional 1,739 shares during the period. Finally, IFP Advisors Inc increased its position in shares of DENTSPLY SIRONA by 924.5% in the second quarter. IFP Advisors Inc now owns 3,811 shares of the medical instruments supplier’s stock worth $61,000 after acquiring an additional 3,439 shares in the last quarter. 95.70% of the stock is currently owned by hedge funds and other institutional investors.

DENTSPLY SIRONA Price Performance

Shares of NASDAQ XRAY opened at $12.05 on Wednesday. The company has a quick ratio of 0.99, a current ratio of 1.47 and a debt-to-equity ratio of 1.36. DENTSPLY SIRONA Inc. has a fifty-two week low of $9.85 and a fifty-two week high of $20.59. The business has a 50 day moving average price of $11.40 and a two-hundred day moving average price of $12.94. The firm has a market cap of $2.40 billion, a PE ratio of -2.73, a price-to-earnings-growth ratio of 0.94 and a beta of 1.00.

DENTSPLY SIRONA (NASDAQ:XRAY) last released its earnings results on Thursday, November 6th. The medical instruments supplier reported $0.37 EPS for the quarter, missing the consensus estimate of $0.45 by ($0.08). DENTSPLY SIRONA had a negative net margin of 24.34% and a positive return on equity of 17.10%. The business had revenue of $904.00 million for the quarter, compared to analysts’ expectations of $900.33 million. During the same quarter last year, the company posted $0.50 earnings per share. The business’s quarterly revenue was down 4.9% compared to the same quarter last year. DENTSPLY SIRONA has set its FY 2025 guidance at 1.600-1.600 EPS. Sell-side analysts expect that DENTSPLY SIRONA Inc. will post 1.84 earnings per share for the current fiscal year.

DENTSPLY SIRONA Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, January 9th. Stockholders of record on Friday, December 26th were given a $0.16 dividend. The ex-dividend date of this dividend was Friday, December 26th. This represents a $0.64 annualized dividend and a dividend yield of 5.3%. DENTSPLY SIRONA’s payout ratio is presently -14.48%.

Insider Buying and Selling at DENTSPLY SIRONA

In other news, Director Gregory T. Lucier sold 82,200 shares of the company’s stock in a transaction dated Monday, December 8th. The shares were sold at an average price of $11.14, for a total value of $915,708.00. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 0.52% of the company’s stock.

Wall Street Analysts Forecast Growth

XRAY has been the topic of several recent research reports. Zacks Research lowered shares of DENTSPLY SIRONA from a “hold” rating to a “strong sell” rating in a report on Monday, November 10th. Wells Fargo & Company cut their price objective on DENTSPLY SIRONA from $15.00 to $12.00 and set an “equal weight” rating on the stock in a research report on Friday, November 7th. UBS Group decreased their target price on DENTSPLY SIRONA from $24.00 to $23.00 and set a “buy” rating for the company in a research report on Tuesday, October 28th. Mizuho raised their target price on DENTSPLY SIRONA from $13.00 to $14.00 and gave the company a “neutral” rating in a report on Tuesday. Finally, Robert W. Baird decreased their price target on DENTSPLY SIRONA from $14.00 to $12.00 and set a “neutral” rating for the company in a report on Tuesday, December 16th. Two equities research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and three have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Reduce” and an average target price of $15.23.

DENTSPLY SIRONA Profile

Dentsply Sirona Inc (NASDAQ: XRAY) is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.

The company’s product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.